Research
From the bench to the bedside to the build.
Dr. Bander’s research joins translational science, clinical trials and applied AI. Current work centers on AI in clinical workflow, quantum sensing for ischemia detection, and anti-inflammatory and metabolic therapies in heart failure and atherosclerotic disease.
42papers and published abstracts
25clinical trials, 14 active
6as principal investigator
13h-index, Google Scholar, November 2026
Themes
Three questions that run through the work
AI in clinical workflow
Can clinicians build and validate their own AI tools?
Studies of conversational AI for pre-procedure patient calls, AI-assisted documentation, a mobile platform for STEMI transfer, and decision support in skilled nursing facilities.
Quantum sensing
Can the heart’s magnetic field reveal ischemia at the bedside?
Principal investigator on the MCG Discovery, DUET and PRISM2 studies of unshielded magnetocardiography in emergency and inpatient settings.
Residual risk
Which new therapies lower risk that standard care leaves behind?
Investigator on trials of IL-6 inhibition, aldosterone synthase inhibition, obesity-targeted therapy and cardiac myosin modulation in heart failure and atherosclerotic disease.
Selected publications
A short reading list
Conversational artificial intelligence for pre-procedural patient preparation: implementation, validation and patient satisfaction
Evidence that anemia accelerates AS progression via shear-induced TGF-β1 activation: Heyde’s syndrome comes full circle
Mobile application to optimize care for ST-segment elevation myocardial infarction patients in a large healthcare system (STEMIcathAID): rationale and design
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Clinical implications of SARS-CoV-2 interaction with the renin–angiotensin system: JACC Review Topic of the Week
Telehealth for identification, treatment, and patient self-management of hypertension: a Mount Sinai Health System novel screening approach for NYC firefighters
Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
Clinical trials
Trials as an investigator
Sponsors are named for transparency. See also disclosures.
| Study | Focus | Role | Dates |
|---|---|---|---|
| PRISM2 SandboxAQ | Open-label, multi-arm prospective investigation of ischemia using the SandboxAQ magnetocardiography device. | PI | Oct 2025 – present |
| DUET SandboxAQ | Magnetocardiography in patients with elevated troponin. | PI | Aug 2024 – Aug 2025 |
| MCG Discovery SandboxAQ | Magnetocardiography in emergency departments. | PI | Oct 2023 – Jul 2025 |
| CHF Screening Test Pilot Icahn School of Medicine at Mount Sinai | AI analysis of speech and cough in patients with congestive heart failure. | PI | Nov 2020 – Oct 2023 |
| CorEFS benchmark (PBH-COREFS-1-A) Peerbridge Health | Benchmarks an AI system that estimates ejection-fraction severity category from continuous ECG waveforms recorded on a wearable device. | Sub-investigator | Oct 2024 – present |
| TRANSFORM Cleerly | Pragmatic randomized trial testing whether a coronary CT angiography–based plaque staging strategy reduces cardiovascular events compared with standard risk-factor–based care. | Sub-investigator | May 2025 – present |
| HERMES Novo Nordisk | Cardiovascular outcomes trial of ziltivekimab versus placebo in heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. | Sub-investigator | Nov 2023 – present |
| ATHENA Novo Nordisk | Ziltivekimab versus placebo on symptoms and physical function in heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. | Sub-investigator | Aug 2024 – present |
| ZEUS Novo Nordisk | Ziltivekimab versus placebo on cardiovascular outcomes in atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation. | Sub-investigator | Apr 2023 – present |
| POSEIDON Novo Nordisk | Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure. | Sub-investigator | Feb 2025 – Aug 2025 |
| Selnoflast phase Ic (GC43343) Genentech | Safety, pharmacokinetics and pharmacodynamics of selnoflast in coronary artery disease with elevated hsCRP. | Sub-investigator | May 2023 – May 2024 |
| AMBER Cytokinetics | Safety, tolerability, pharmacokinetics and pharmacodynamics of CK-4021586 in symptomatic heart failure with preserved ejection fraction. | Sub-investigator | Jan 2026 – present |
| MARITIME-HF Amgen | Phase 3 trial of maridebart cafraglutide on mortality and morbidity in heart failure with preserved or mildly reduced ejection fraction and obesity. | Sub-investigator | Nov 2025 – present |
| EASi-HF Reduced Boehringer Ingelheim | Phase 3 trial of vicadrostat with empagliflozin versus placebo with empagliflozin in symptomatic heart failure with ejection fraction below 40%. | Sub-investigator | Nov 2025 – present |
| EASi-HF Boehringer Ingelheim | Phase 3 trial of vicadrostat with empagliflozin versus placebo with empagliflozin in symptomatic heart failure with ejection fraction of 40% or higher. | Sub-investigator | Feb 2025 – present |
| SONATA-HCM Lexicon | Phase 3 trial of sotagliflozin in symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy. | Sub-investigator | Jun 2025 – present |
| Tovinontrine in HFpEF (CRD-750-202) Cardurion Pharmaceuticals | Phase 2 trial of tovinontrine versus placebo in chronic heart failure with preserved ejection fraction. | Sub-investigator | Aug 2024 – Mar 2026 |
| Tovinontrine in HFrEF (CRD-750-201) Cardurion Pharmaceuticals | Phase 2 trial of tovinontrine versus placebo in chronic heart failure with reduced ejection fraction. | Sub-investigator | Aug 2024 – Mar 2026 |
| PROACTIVE-HF-2 Endotronix | Randomized trial of a pulmonary artery pressure sensor system in NYHA class II–III heart failure. | Sub-investigator | Jul 2024 – present |
| VICTORION-2 PREVENT Novartis | Randomized trial of inclisiran on major adverse cardiovascular events in established cardiovascular disease. | Sub-investigator | Jun 2022 – present |
| AZ TRACK AstraZeneca | Prospective, non-interventional study of the treatment journey of adults with hyperkalemia. | Sub-investigator | Apr 2023 – Jul 2025 |
| FREEDOM COVID Icahn School of Medicine at Mount Sinai | Randomized trial comparing anticoagulation strategies in hospitalized patients with COVID-19. Mount Sinai was the primary site. | Sub-investigator | Sep 2020 – Aug 2023 |
| PK Papyrus (HDE) Icahn School of Medicine at Mount Sinai | Humanitarian Device Exemption covered coronary stent system for acute coronary perforations. | Sub-investigator | Feb 2020 – present |
| THEMIS AstraZeneca | Phase 3 trial of ticagrelor versus placebo on cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes. | PI | Mar 2016 – Mar 2019 |
| ARTEMIS AstraZeneca | Affordability and real-world antiplatelet treatment effectiveness after myocardial infarction. | PI | Mar 2016 – Sep 2016 |
Publications
Full list
Conversational artificial intelligence for pre-procedural patient preparation: implementation, validation and patient satisfaction
Evaluation of a human-in-the-loop pre-procedural clinical conversational AI calling system for cardiac catheterisationAbstract
Clinical integration of an AI-augmented platform for pre-procedural cardiac catheterisation preparationAbstract
Scalability of a mobile care coordination platform to optimise inter-hospital STEMI transfer workflows: health system expansionAbstract
TCT-443: Evaluation of AI-assisted virtual agent for pre-procedural patient calling in the cardiac catheterization laboratoryAbstract
Evidence that anemia accelerates AS progression via shear-induced TGF-β1 activation: Heyde’s syndrome comes full circle
Plasma transforming growth factor-β1 levels increase with age and aortic stenosis progression and low-dose galunisertib attenuates disease progression in miceAbstract
Deploying a novel custom mobile application for STEMI activation and transfer in a large healthcare system to improve cross-team workflow: STEMIcathAID implementation project
TCT-472: Deploying a custom STEMI transfer application in a large healthcare system to improve cross-team workflowAbstract
Mobile application to optimize care for ST-segment elevation myocardial infarction patients in a large healthcare system (STEMIcathAID): rationale and design
Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients
Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai Health System
A novel mobile application to diagnose and transfer patients with STEMI in a large healthcare system: STEMIcathAIDAbstract
Multimodality cardiovascular imaging in COVID-19 patientsAbstract
Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Clinical implications of SARS-CoV-2 interaction with the renin–angiotensin system: JACC Review Topic of the Week
Reengineering the discharge management of heart failure patients discharged to skilled nursing facilities utilizing a multidisciplinary team approach reduces 30-day readmissionAbstract
Telehealth for identification, treatment, and patient self-management of hypertension: a Mount Sinai Health System novel screening approach for NYC firefightersAbstract
Patient experience with digital navigation during cardiac catheterization: early findings from ACC Digital Transformation Network Pioneer CohortAbstract
Hospital readmissions from nursing homes dramatically reduced using a novel, cost-effective heart failure protocolAbstract
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous PCI (THEMIS-PCI): a phase 3 placebo-controlled trial
TCT-451: Incidence, correlates and impact of left ventricular ejection fraction improvement on clinical outcomes of patients undergoing high-risk PCIAbstract
New methodologies to accurately assess circulating active TGF-β1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices
Renal cell carcinoma with inferior vena cava thrombus extending to the right atrium diagnosed during pregnancy
Nursing home readmissions reduced using a novel heart failure protocolAbstract
An allele-specific PCR system for rapid detection and discrimination of the CYP2C19*4A, *4B, and *17 alleles
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
Validation of real-time 3D echocardiography left ventricular volume-time curves with cardiac MRI and utilization of emptying and filling rates
Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
Physiologic impact of chronic kidney disease on whole blood clot kinetics and strengthAbstract
Hematologic changes in vWF-dependent platelet aggregation after LVAD implantation: a prospective studyAbstract
Active TGF-β1 is more commonly detectable in plasma of patients with aortic stenosis than catheterization controlsAbstract
Real-time 3-D echo-generated volume/time curves: comparison to MRI and interobserver correlationAbstract
Independent and combined impact of diabetes and CKD on platelet reactivityAbstract
First documentation of cardiac dysfunction following exposure to the World Trade Center disasterAbstract
Balloon aortic valvuloplasty and surgical AVR reverse vWF abnormalities in severe ASAbstract
Validation of real-time 3-D echo derived volume/time curves by MRIAbstract
Further characterizations of human CD4+CD25+ regulatory T-cellsAbstract
Expression of Q227L-Gαs in MCF-7 human breast cancer cells inhibits tumorigenesis
Live from PubMed
Most recently indexed
Refreshed automatically each time the site is rebuilt. Last checked 2026-11-12.